| immatics to Receive Support From Pfizer for its Pivotal Phase III Study ... - DigitalJournal.com (press release) |
|
|
DigitalJournal.com (press release) The pivotal Phase III study will evaluate as the primary endpoint the overall survival of advanced renal cell carcinoma patients treated with IMA901 in combination with Pfizer's Sutent(R) (sunitinib malate) versus Sutent(R) alone. |